Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
82 Cards in this Set
- Front
- Back
Primary prevention:
|
activities to prevent the onset of a disease
|
|
Secondary prevention:
|
activities to ID and tx asx persons with RF's for a disease; "secondary = screening"
|
|
Goal of primary prevention:
|
spare individuals the suffering, burden, and cost of the condition
|
|
Examples of primary prevention:
|
immunization, chemoprophylaxis
|
|
active immunity is:
|
resistance developed in response to an Ag
|
|
tertiary prevention:
|
management of a person with an established disease
|
|
goal of tertiary prevention:
|
minimize disease-associated complications
|
|
examples of tertiary prevention:
|
meds & lifestyle changes to moderate BG in DM
|
|
Problems with using amantadine or rimantadine for influenza:
|
some influenza strains are resistant
|
|
Zanamivir (Relenza) or oseltamivir (Tamiflu) in care of pt's with or at risk of influenza:
|
these d's can minimize severity if used early in acute illness
|
|
Does influenza nasal spray contain LAVV?
|
Yes, nasal spray influenza vaccine is live and attenuated.
|
|
% of HCP's receive influ vaccination annually
|
40% receive the influ vaccination
|
|
For nml adult, length of inoculation for influ is:
|
1-4 d
|
|
children with influ present with:
|
AOM, n/v
|
|
influ sx resolve within
|
1 week, but cough and malaise often last 2 w
|
|
influ largely spread via:
|
respiratory droplets (cough or sneeze)
|
|
adults with influ remain contagious for how many days after onset of sx?
|
5 days
|
|
children with influ remain contagious for how many days after onset of sx?
|
10 days
|
|
immunocompromised with influ remain contagious for how many days after onset of sx?
|
3 weeks
|
|
influ vaccines are _% effective in preventing influ.
|
70-80%
|
|
who should not receive FluMist?
|
(good for 2-49y/o)
NOT for <2y/o, >50y/o, pt with a medical condition like CHD, lung disease, DM, renal disease, and immunosuppression; children / adolescents on LT ASA, pt with hx of GBS, pregnancy, allergy to eggs |
|
Influ vaccinate when?
|
1 month prior to season, usually in October or November
|
|
Influ Special considerations for < 9y/o:
|
if initial dose of influ vaccine, need two doses
|
|
MMR vaccine:
|
live, attenuated; 2 doses, 1 month apart; typically causes mild 3-5 d illness; teratogenic if contracted during pregnancy; DON'T give in pregnancy; Not for allergy to neomycin or gelatin, safe during lactation
|
|
pneumococcal disease:
|
G+ streptococcus pneumoniae (leading CoD from CAP in US); also - atypical: M. Pneumo, Chlamydophila, Legionella; G-: H. Influ, Moraxella catarrhalis, and Klebsiella pneumo
|
|
pneumococcal vaccine
|
vaccine with 23-valent polysaccharide (ineffective against M. Pneumo, Chlamydophila, Legionella; G-: H. Influ, Moraxella catarrhalis, and Klebsiella pneumo)
|
|
indications for pneumo vaccine
|
chronic lung disease, CVD, chronic liver disease, splenectomy, immunocompromised, cochlear implants, CSF leak, HIV; residents of nursing homes, smokers, adults >65y/o
|
|
indications for repeat pneumo vaccine, after 5 years:
|
chronic renal failure, asplenia, immunocompromised; OR if >65y/o and was 5 years or more previously AND younger than 65 y/o at time of primary vaccination
|
|
HBV vaccine contraindication:
|
hx of reaction to baker's yeast
|
|
Risks associated with chronic HBV:
|
hepatocellular carcinoma, cirrhosis, continued infectivity
|
|
structure of HBV:
|
double-stranded DNA virus with inner core protein of HBV core Ag and an outer surface of HBsAg
|
|
transmission of HBV
|
blood or body fluids
|
|
% of acute HBV that becomes chronic:
|
5%
|
|
HBV vaccine
|
non-live vaccine, 3 doses required, 95% of those receiving it develop HBsAb
|
|
high risk people needing HBsAb testing:
|
HC, injection drug users, sex workers, dialysis pt's, immunosupressed
|
|
when to admin booster of HBV vaccine:
|
when HBsAb levels decline to < 10mIU/mL
|
|
post exposure prophylaxis for HBV (and many other potential infections):
|
HBIG ASAP - preferred within 24 hours - and HBV vaccine; also offer testing for HIV, HAV, HCV
|
|
if allergic to neomycin, avoid which vaccines?
|
IPV, MMR, varicella
|
|
if allergy to streptomycin, polymyxin B, neomycin, avoid which vaccines?
|
IPV, smallpox
|
|
if allergy to Baker's yeast, avoid which vaccine?
|
HBV
|
|
if allergy to egg, avoid which vaccine?
|
influenza - either form
|
|
if allergy to gelatin, avoid which vaccine
|
MMR, varicella
|
|
smallpox spread:
|
direct deposit of infective droplets
|
|
smallpox virus name:
|
variola; variola major is m/c and most severe (fatality 30%)
|
|
smallpox characteristics:
|
incubation: 7-17d without sx and not contagious; rash starts on tongue and spreads to face, arms, legs, hands, feet within 24 hours (all at the same time); contagious until all crusts have fallen off
|
|
varicella (AKA chickenpox or VZV) characteristics:
|
lesions erupt over several days, old and new lesions
|
|
smallpox vaccination:
|
in anticipation of bioterrorism: give within 3 d of exposure; if given 3-7d post-exposure, some benefit; made from LIVE smallpox relative called "vaccinia"; vaccination itself WILL cause large draining pustule / scar
|
|
% who develop shingles after primary infection with VZV:
|
15%; markedly reduced in those with vaccination; should confirm VZV immunity via titers in HCP
|
|
varicella vaccine schedule:
|
1-1year
2-4-6y/o |
|
if older adult w/o hx of varicella or VZV vaccine, vaccine schedule:
|
2 doses, 4-8w apart
|
|
partum pt w/o hx of VZV immunity receives:
|
dose one of VZV vaccine prior to hospital discharge
|
|
VZV vaccine characteristics:
|
live, attenuated; can cause mild chickenpox
|
|
LAVV precautions:
|
MMR - pregnancy
VZV (chick) - immunosuppression (except HIV); if HIV, don't give if CD4 <200 cell/uL FluMist |
|
tetanus characteristics:
|
clostridium tetani - anaerobe, G+, found in soil
|
|
diptheria characteristics:
|
corynebacterium diphtheriae, G- bacillus; causes severe resp. tract infection - pseudomembranous pharyngitis; transmission person-to-person or contaminated liquids
|
|
tetanus booster?
|
q 10 y
|
|
Tdap given in adulthood
|
covers tetanus for 10 years and pertussis
|
|
m/c source of HAV infection:
|
contaminated drinking water
|
|
characteristics of HAV:
|
small RNA virus; fecal-oral transmit, self-limiting infection; in developing countries, most children develop it by 5y/o; in N. America, 50% of cases are 20-39y/o
|
|
HAV immunization schedule:
|
2 doses 6-12 m apart; not live virus
|
|
poliovirus:
|
transmit fecal-oral, highly contagious: rates of household contact infection are up to 96%!
|
|
poliovirus vaccine:
|
live (oral, small stool shedding with possible infection consequence; no longer used in USA) or inactive (IM)
|
|
recommended screening for a 55 y/o woman:
|
breast, skin, colorectal
|
|
Br CA screening:
|
>20y/o BSE
20-30y/o CBE q 3 y; asx pt's >= 40y/o q y |
|
Mammography screening guidelines:
|
>=40y/o q year; with high risk both mammo and MRI q y
|
|
colorectal screening guidelines:
|
men and women >=50y/o -> FOBT at Home! (2 samples from 3 consecutive specimens; NOT toilet-bowl specimens); if any +, go with colonoscopy; OR stool DNA test
|
|
colorectal imaging guidelines:
|
flexible sigmoidoscopy q 5y at 50y/o OR
DCBE q 5y at 50y/o OR colonoscopy q 10y at 50y/o |
|
RF's for colorectal cancer (warranting increased screening):
|
hx of CR CA, Crohn's / UC, family hx of <60y/o of CR CA or polyps, fix of hereditary colorectal CA syndromes
|
|
prostate screening:
|
>=50y/o; OFFER DRE and PSA annually for men with life expectancy greater than 10 y
|
|
higher risk for prostate CA - increase screening:
|
AA, fhx of dx <65y/o -> start at 45y/o with screening; if multiple 1st degree male relatives, start screening at 40y/o
|
|
cervical CA screening:
|
PAP
start 3 y after first sex - not later than 21y/o; q y with PAP; at 30y/o women with 3 nml PAPs screen q 2-3y; >70y/o with 3 or more nml PAPs and no abnl in past 10 y can STOP cervical CA screening |
|
components of intervention for treating tobacco use:
|
ask, advise assess, assist, arrange - the "Five A's"
use in ALL cases of tobacco use and at all encounters |
|
varenicline used for and SE's:
|
smoking cessation depressed mood, agitation, changes in behavior, suicidal ideation, and suicide; ask about suicideality at every visit
|
|
corneal reflex from CN:
|
V
|
|
vision and visual fields CN:
|
III
|
|
Mnemonic for the CN's:
|
On Old Olympus Towering Tops, A Finn And German Viewed Some Hops
|
|
trochlear n innervates what:
|
it is CN IV: innervates the Superior oblique muscle
|
|
normal corneal reflexes are innervated by:
|
the afferent limb of CN V and the effect limb of CN VII
|
|
what are effects from CN IX and X:
|
Glossopharyngeal: swallowing, palate elevation, gustation
|
|
CN X does:
|
parasympathetic regulation of multiple organs: sensing aortic pressure and regulating BP, slowing HR, regulating taste and digestive tract
|
|
decreased facial tonus - including eyelid drooping - caused by which affected CN?
|
CN VII; if suspected, perform a Lyme Ab titer; if treating Bell's Palsy, use prednisone PO ASAP (this tx is useless after > 10d from onset)
|
|
Bell's Palsy etiology?
|
could be Lyme; possibly HHV or Varicella-zoster; tx: supportive care, keep the eye protected and moist
|